MEMeltem Akgül Erdal

Meltem Akgül Erdal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Meltem Akgül Erdal has a total of 146 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical and Genetic Landscape of Primary Ciliary Dyskinesia in Turkey: A Single‐Center Retrospective Cohort Study on Genotype–Phenotype Correlations

    by Aslı Kuzu Kuşaklı, Nagehan Emiralioğlu, Birce Sunman, Meltem Akgül Erdal, Didem Alboğa, Burcu Çapraz Yavuz, Sevilay Karahan, Elif Karakoç, Elmas Ebru Yalçın, Deniz Doğru Ersöz, et al.

    Background: Primary ciliary dyskinesia (PCD) is a genetic disorder impairing mucociliary clearance. This study provides a comprehensive analysis of clinical and genetic characteristics in a large Turkish cohort with frequent parental consanguinity. Methods: A retrospective cohort study was performed on 145 patients (selected from 361) with regular follow‐up since 2017 to ensure longitudinal data consistency. The diagnostic work‐up included nasal nitric oxide measurement and high‐speed videomicroscopy, while confirmation was established through genetic testing and/or transmission electron microscopy. Patients were classified according to the 2025 ATS/ERS diagnostic framework. Patients were evaluated for clinical predictors, longitudinal pulmonary function, and genotype–phenotype correlations based on structural protein localization. Results: Among 145 patients (mean age 15.91 ± 6.26 years), early diagnosis was significantly associated with neonatal respiratory distress syndrome ( p = 0.014), NICU admission ( p < 0.001), situs inversus totalis ( p < 0.001), and congenital heart disease ( p < 0.001). The mean PICADAR score was 7.8 ± 3.4, showing a moderate negative correlation with age at diagnosis ( r = −0.50, p < 0.001). According to the 2025 ATS/ERS diagnostic framework, 63 patients (43.4%) were classified as confirmed PCD, 13 (9.0%) as PCD highly likely, and 69 (47.6%) as suspected PCD. Among confirmed PCD patients, the most frequent genetic findings were DNAH5, CCDC40 , and DNAAF1 . Lower final FEV1 values were observed in selected rare genotype subgroups, particularly CCNO , although variant‐specific comparisons were limited by small subgroup sizes. Conclusion: Early recognition of neonatal respiratory distress requiring NICU admission and laterality defects, particularly situs inversus totalis, remains critical for reducing diagnostic delay. In populations with high consanguinity, genetic testing is particularly important for confirming diagnosis and identifying potentially high‐risk genotypes. Multidisciplinary follow‐up focusing on nutrition, infection control, and preservation of lung function is essential for long‐term care in PCD.

  • Longitudinal Impact of Pseudomonas aeruginosa Versus Haemophilus influenzae Colonization on Lung Function Decline in Children With Primary Ciliary Dyskinesia

    by Ömer Faruk İpEk, Nagehan Emiralioğlu Ordukaya, Aslı Kuzu Kuşaklı, Meltem Akgül Erdal, Havva İpEk Demir, Ebru Yalçın, Deniz Doğru, Uğur Özçelik

    Background: The association of Pseudomonas aeruginosa (PsA) and Haemophilus influenzae (HI) colonization with lung function in children with primary ciliary dyskinesia (PCD) remains insufficiently defined. We aimed to compare spirometric parameters between PsA‐ and HI‐colonized children and evaluate longitudinal changes before, at, and after chronic colonization. Methods: This retrospective cohort included patients aged ≥ 5 years with definite or highly probable PCD and chronic PsA or HI colonization. Chronic colonization was defined using repeated sputum cultures over 12 months. Pulmonary function tests were analyzed 1 year before colonization, at colonization, and 1 year after colonization. FEV1, FVC, and FEF25–75 were reported as percent‐predicted values and GLI 2012 z‐scores. Individual pre‐to‐after‐colonization change scores and bronchiectasis subgroup analyses were performed. Results: Among 290 patients with PCD, 40 met inclusion criteria: 10 with PsA and 30 with HI colonization. PsA‐colonized patients were older at colonization than HI‐colonized patients (17 [12–23] vs. 11 [9–15] years, p = 0.011), and bronchiectasis was more frequent in the PsA group (100% vs. 60%, p = 0.019). PsA colonization was associated with lower lung function across several spirometric measures. Both groups showed significant within‐group declines in FEV1 and FEF25–75 over time. However, individual pre‐to‐after‐colonization changes in FEV1 and FEF25–75 z‐scores did not differ significantly between groups, including in the bronchiectasis subgroup analysis. Conclusions: PsA colonization was associated with lower lung function than HI colonization, but not with significantly greater longitudinal decline. These findings suggest that PsA may mark more advanced disease rather than independently accelerating functional loss. Larger prospective studies with non‐colonized comparators are needed.

  • Exploring Social Determinants of Health in Primary Ciliary Dyskinesia

    by Meltem Akgül Erdal, Tuğçe Kantemir, Ömer Faruk İpEk, Deniz DoğrU, Ebru Yalçın, Nagehan Emiralioğlu, UğuR ÖzÇeLik

    Background: Primary ciliary dyskinesia (PCD) is a genetic ciliopathy characterized by a diverse clinical presentation with marked respiratory complications and adversely impacts quality of life. However, the lived experience of individuals with PCD extends beyond biological complications, intersecting with social determinants of health (SDoH). The role of SDoH in the context of PCD remains insufficiently characterized. Objective: This cross‐sectional study aimed to assess the current picture of SDoH insecurity among primary caregivers of pediatric PCD/highly likely PCD patients. Methods: The study was conducted at a tertiary care center in Türkiye, from March 1 to October 31, 2024. Primary caregivers of children aged 6–18 years with PCD/highly likely PCD were surveyed using the “Your Current Life Situation” questionnaire. Data on caregiver demographics, income, education, smoking status, and household conditions were collected. Clinical data (BMI, FEV1, hospitalizations, and annual antibiotic courses) were retrieved from patient records. Descriptive statistics and nonparametric tests were applied using SPSS 22.0. Results: Among 67 respondents (response rate: 73%), 89.6% reported insecurity in ≥ 1 of six SDoH domains. The most common issues were social support/stress (73.1%), healthcare access (53.7%), and financial hardship (49.3%). Most families (86.5%) lived below the poverty line; 55.2% of caregivers had inadequate health literacy. Conclusions: A high prevalence of SDoH insecurity was identified among caregivers of children with PCD/highly likely PCD, highlighting unmet psychosocial and healthcare access needs. The substantial proportion of caregivers requiring support underscores the the need for routine SDoH screening, caregiver support, and targeted interventions to promote health equity in PCD patients.

  • Open Access

    Tuberculosis infection in BCG vaccinated children and adolescents with rheumatological diseases treated by tumor necrosis factor-α inhibitors

    by Dilber Ademhan Tural, Deniz Doğru, Beste Özsezen, Azer Karaman, Birce Sunman, Halime Nayir Büyükşahin, İsMail Güzelkaş, Didem Alboğa, Meltem Akgül Erdal, Nagehan Emiralioğlu Ordukaya, et al.

    Tumor necrosis factor-alpha (TNF-α) inhibitors increase the risk of developing active tuberculosis (TB) disease through reactivation of latent TB infection (LTBI). We aimed to analyze TB infections in BCG-vaccinated children and adolescents with rheumatologic diseases treated with TNF-α inhibitors in a country of moderate risk for TB. This retrospective study included 261 children with a rheumatic disease who were treated with TNF-α inhibitors and followed up on a fixed schedule between January 2018 and December 2022. Demographic and clinical characteristics, as well as TB screening results, were recorded. The mean age of the patients was 14.0 ± 4.1 years; 56.7% were female. The mean age at initiation of TNF-α inhibitors was 11.0 ± 5.1 years, the mean duration of TNF-α inhibitor use was 4.1 ± 2.7 years, and the mean follow-up time was 4.1 ± 2.6 years. During the study period, 75 (29.0%) patients were diagnosed with LTBI: 44% at the initial evaluation and 56% during follow-up. None of them progressed to TB disease. Only two cases of active TB disease were seen without prior documented LTBI. Age and duration of TNF-α inhibitor use were significantly associated with LTBI positivity. Conclusion : TB screening is necessary in children and adolescents at the initiation of and during TNF-α inhibitor therapy. The risk of LTBI positivity increases with age and longer use of TNF-α inhibitors. No cases progressed from LTBI to active TB, which may support the effectiveness of current screening and prophylaxis strategies in our country. What is Known: • TNF-α inhibitors are associated with an increased risk of developing active tuberculosis (TB) disease as a result of the reactivation of latent TB infection (LTBI). What is New: • Screening for LTBI at initiation and during TNF-α inhibitor treatment, along with appropriate LTBI prophylaxis, prevented LTBI reactivation into active TB disease in BCG-vaccinated patients receiving TNF-α inhibitors. • Increasing age and duration of TNF-α inhibitor treatment are associated with the risk of LTBI positivity.

  • Primary Ciliary Dyskinesia: Do We Need to Test for Primary Immune Deficiency Routinely?

    by Halime Nayir Buyuksahin, Nagehan Emiralioglu, Canan Caka, Saliha Esenboğa, Deniz Cagdas, Raziye Atan, İsMail Yaz, Ismail Guzelkas, Birce Sunman, Didem Alboga, et al.

    Background: Primary Ciliary Dyskinesia (PCD) and predominantly antibody deficiencies (PAD) are among the important causes of recurrent respiratory tract infections from childhood and require different treatment strategies. The primary aim of this study was to investigate the coexistence of PCD and PAD in a cohort of patients diagnosed with PCD at a tertiary care hospital. Our secondary aim was to determine the association between the ultrastructural phenotype and the type of immune disorder. Methods: Sixty‐two patients with PCD were enrolled in the study. Complete blood count, serum immunoglobulin levels, isohemagglutinin levels, serum IgG subgroups, and lymphocyte subgroups were evaluated. PAD was defined as a serum immunoglobulin level more than 2 SDs below the age‐adjusted normal mean. Patients with an immunological abnormality are labeled Group 1, and those with normal immunological results are labeled Group 2. Results: The mean age was 12.8 ( ± 5.8) years, with an equal male‐to‐female ratio. Twenty‐six patients (41.9%) exhibited abnormal results during the immunological evaluation (Group 1). These immunological abnormalities included lymphopenia, a reversed CD4/CD8 ratio, lymphocyte subgroup deficiencies, and serum immunoglobulin levels outside the normal range. There was no significant difference between the groups in terms of having pulmonary exacerbations in the previous year (38% vs. 38%, p = 0.97), mean ppFEV1 (83.8% vs. 79.5%, p = 0.44), having chronic colonization ( p = 0.75), and ultrastructural phenotype ( p = 0.17). Patients with detected immunological abnormalities were taken under follow‐up by the immunology department, antibiotic prophylaxis was initiated, and vaccinations were planned in some cases. Conclusions: Routine immunological evaluation of patients diagnosed with PCD may be beneficial since individualized treatment options are present in the management of PAD.

  • Open Access

    Quality of life in Turkish children with interstitial lung disease: Insights from the National chILD Registry

    by Handan Kekec, Tugba Sismanlar Eyuboglu, Ayse Tana Aslan, Ozge Ulgen, Aslıhan Ozcaglar, Zeliha Başak Polat, Betül Bankoglu Parlak, Aysen Bingol, Seyda Karabulut, Ela Erdem Eralp, et al.

    Childhood interstitial lung diseases (chILD) include a diverse range of rare disorders, complex clinical progressions, and high rates of morbidity and mortality. This study aims to assess the clinical and psychosocial impacts of chILD in children registered in the National chILD-Turkiye database. Data from 17 centers were analyzed as of January 2024. Patients aged 1 month to 18 years were included in the study. Through face-to-face interviews, patients and their families completed the Pediatric Quality of Life Inventory (PedsQL™ 4.0 Generic Core Scales) and PedsQL™ 2.0 Family Impact Module. Higher scores suggest better performance and higher health-related quality of life (HRQoL). Patient clinic data, demographic information, pulmonary function tests, Fan scores, and household income were recorded. Patients were categorized into two groups according to their use of O 2 therapy and diffuse progressive lung disease (DPLD) groups A and B. The study included 175 patients (90 girls), with a median age of 7.7 (1.0–17.8) years. A strong positive correlation was found between the FEV1% value and both the Physical Health Summary Score and the Total Score ( p = 0.007, r = 0.608; p = 0.008, r = 0.607). The Fan score negatively correlated with PedsQL™ scores ( p < 0.001). Patients who use O 2 have an earlier diagnosis of age of chILD, lower FEV1%, higher Fan scores, and lower Child Self-Reports and Parent Reports scores ( p < 0.05). The group with DPLD-A disorders has an earlier diagnosis age, lower weight and BMI z-scores, higher Fan score, and higher Family Impact Module score ( p < 0.05). Conclusion : Lung function and Fan score strongly correlate with HRQoL, emphasizing the impact of disease severity on physical and psychosocial well-being. These findings highlight the need for multidisciplinary care and psychosocial support to enhance the QoL in children with chILD and their families. What is Known: • Childhood interstitial lung diseases (chILD) are rare and diverse disorders associated with significant morbidity and complex management. • Evidence regarding health-related quality of life (HRQoL) and the psychosocial burden on affected families remains limited. What is New: • This multicenter national registry–based study provides the first comprehensive evaluation of HRQoL and family impact in children with chILD in Türkiye. • Lung function impairment and higher Fan severity scores were strongly linked to poorerHRQoL, highlighting the influence of disease severity on physical and psychosocial well-being.

  • Variable Response to Elexacaftor/Tezacaftor/Ivacaftor in [L467F;F508del] Homozygous Patients: A Case Series

    by Meltem Akgül Erdal, Ebru Yalçın, Ahmet Cevdet Ceylan, Didem Dayangaç, Ela Erdem Eralp, Nagehan Emiralioğlu, Deniz Doğru, Uğur Özçelik

  • Open Access

    Airway obstruction and gender affect arterial stiffness in children with cystic fibrosis

    by Senem Şimşek, Aslıhan Çakmak Önal, Meltem Akgül Erdal, Yasemin Kartal, Murat Timur Budak, Suna Sabuncuoğlu, Nagehan Emiralioğlu, Elmas Ebru Güneş Yalçın, Deniz İnAl İnCe

    Background. Vascular changes are observed in children with cystic fibrosis (cwCF), and gender-specific differences may impact arterial stiffness. We aimed to compare arterial stiffness and clinical parameters based on gender in cwCF and to determine the factors affecting arterial stiffness in cwCF. Methods. Fifty-eight cwCF were included. Pulmonary function, lean body mass, handgrip strength, and peak oxygen uptake (VO2peak) were assessed using a cardiopulmonary exercise test. Arterial stiffness (pulse wave velocity [PWV] and augmentation index [AIx@75]) and hemodynamic parameters (resting heart rate [HR] and stroke volume [SV]) were measured using brachial pulse waves. Endothelial function (ICAM-1, sVCAM-1, sE-selectin, VEGF-A, ET-1) was evaluated using blood samples. Results. Female cwCF had significantly lower VO2peak, SV, and PWV, and higher resting HR, AIx@75, and AIx@75-z-score than male cwCF (p<0.05). AIx@75-z-score was associated with gender (r=0.516, p<0.001), age (r= -0.345, p=0.008), lean body mass (r= -0.451, p<0.001), forced expiratory volume in one second (FEV1)-z-score (r= -0.332, p=0.011), handgrip strength (r= -0.466, p<0.001), and VO2peak (r= -0.459, p<0.001) and peak workload (r= -0.527, p0.05). The FEV1-z-score and gender explained 34.6% of the variance in AIx@75-z-score (p<0.05). Conclusions. Female cwCF have more impaired hemodynamics, less maximal exercise capacity, and increased arterial stiffness, indicating a higher cardiovascular risk compared to male cwCF. FEV1 and gender affect arterial stiffness in cwCF. Further studies are necessary to uncover the underlying factors for arterial stiffness and endothelial dysfunction and their clinical effects in cwCF.

  • Open Access

    Current Status of Cystic Fibrosis in Türkiye: Data from the National Registry

    by Dilber Ademhan Tural, Tuğba Şişmanlar Eyüboğlu, Güzin Cinel, Erkan Çakır, Sevgi Pekcan, Uğur Özçelik, Nagehan Emiralioğlu Ordukaya, Ebru Yalçın, Halime Nayır Büyükşahin, Mahir Serbes, et al.

    The Cystic Fibrosis Registry of Türkiye (CFRT) was established by the Turkish Pediatric Respiratory Diseases and Cystic Fibrosis Society and has provided detailed information on demographic, clinical, genetic, and treatment-related aspects of cystic fibrosis (CF) patients since 2017. We aimed to describe the current status of CF in Türkiye using CFRT's 2023 annual data. Demographic, clinical, and treatment data were taken from CFRT's 2023 record. In 2023, 2,258 patients from 34 centers were recorded. The median age of patients was 9.1 years, and 46.9% were female, with a median age at diagnosis of 0.3 years. Only 14.9% of the patients were older than 18 years. Genetic analyses were completed in 97.3% of patients. The most common variant, F508del, had a total variant frequency of 22.1%. The median percent predicted FEV1 and FVC were 88.0 and 94.0 in those aged 6-17 years 71.0 and 84.0 in those aged ≥18 years, respectively. The median values of body mass index z-scores were -0.5, and -0.5 for patients 2-18 and older than 18 years, respectively. Chronic colonization with Pseudomonas aeruginosa was present in 17.2% of the patients. Most patients used inhaled recombinant human DNase (87.1%) and oral pancreatic enzyme replacement treatment (83.0%). CF transmembrane conductance regulator (CFTR) modulators were used by 15.9% of patients. Over the year, 24 patients died, with a median age at death of 13.3 years. The CFRT report provides a valuable resource showing the clinical and laboratory data of patients with CF in the country.


  • Open Access

    Eligibility of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator therapies: cohort of cystic fibrosis registry of Türkiye

    by Meltem Akgül Erdal, Halime Nayır Büyükşahin, Velat Şen, Ayşe Ayzıt Kılınç, Haluk Çokuğraş, Güzide Doğan, Aslı İmran Yılmaz, Gökçen Ünal, Mahir Serbes, Derya Ufuk Altıntaş, et al.

    Background. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) variants are essential for determining eligibility for CFTR modulator drugs (CFTRms). In contrast to Europe and the USA, the treatment eligibility profile of cystic fibrosis (CF) patients in Türkiye is not known. In this study we aimed to determine the eligibility of CF patients in Türkiye for the CFTRms. Methods. The Cystic Fibrosis Registry of Türkiye (CFrT) data was used to determine the age of patients in the year 2021 and the genetic variants they were carrying. Age- and CFTR-variant appropriate modulator therapies were determined using the Vertex® algorithm. Results. Among a total of 1930 registered patients, CTFR gene analysis was performed on a total of 1841 (95.4%) patients. Mutations were detected in one allele in 10.7% (198 patients), and in both alleles in 79% (1455 patients) of patients. A total of 855 patients (51.7% for whom at least 1 mutation was detected) were eligible for the drugs. The most appropriate drug among genotyped patients was found to be elexacaftor/tezacaftor/ivacaftor for 486 patients (26.4%), followed by ivacaftor for 327 patients (17.7%) and lumacaftor/ivacaftor for 42 patients (2%). Conclusions. Only half of patients registered in CFrT were eligible for CFTRms, which is a significant difference from the CFTR variant profile seen in USA and Europe. However, access to treatment is hampered for some patients whose genes are not analysed. Further studies in CF populations, where rare mutations are relatively more common, will contribute to the field of CFTR modulator treatments for such rare mutations.